Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review)

Stec,Rafał; Bodnar,Lubomir; Smoter,Marta; Mączewski,Michał; Szczylik,Cezary

doi:10.3892/ol.2010.212

Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review)

Authors:
- Rafał Stec
- Lubomir Bodnar
- Marta Smoter
- Michał Mączewski
- Cezary Szczylik
View Affiliations

Affiliations: Department of Oncology, Military Institute of Medicine in Warsaw, 04-141 Warsaw, Poland, Department of Clinical Physiology, Medical Center of Postgraduate Education, Warsaw, Poland
Published online on: November 23, 2010 https://doi.org/10.3892/ol.2010.212
Pages: 3-11

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is one of the most frequently occurring types of cancer. Worldwide, more than 800,000 new cases of CRC are diagnosed each year. The median ages at CRC diagnosis and death are 71 and 75 years, respectively. The majority ot patients (50-60%) with colorectal cancer are diagnosed at stage IV disease. Patients aged 65 or older are characterized by a higher incidence of significant co-morbidities, decreased regenerative capacity of bone marrow and worse general performance. Anti-neoplastic therapies used for the treatment of colorectal cancer include irinotecan, oxaliplatin, 5-fluorouracil, leucovorin, capecitabine and monoclonal antibodies. Analysis of the efficacy of the presented chemotherapeutic and chemoimmunotherapeutic regimens in the treatment of metastatic CRC in patients older than 65 and 70 years compared to ‘younger’ patients, generally demonstrated comparable efficacy, time to disease progression and overall survival. Age criterion should not be considered when assessing the eligibility of patients with metastatic CRC for treatment of the above-mentioned chemotherapeutic and chemoimmunotherapeutic regimens. Treatment should be individualized based on the potential risks and benefits anticipated for each patient.

View Figures

View References

1	Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review 1973–1998. National Cancer Institute; Bethesda, MD: 2001
2	National Institutes of Health. Surveillance epidemiology and end results. Available at: http://seer.cancer.gov/. 2008
3	Adjei AA: A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. J Clin Pharmacol. 48:265–277. 1999. View Article : Google Scholar : PubMed/NCBI
4	Lichtman SM and Villani G: Chemotherapy in the elderly: pharmacologic considerations. Cancer Control. 7:548–556. 2000.PubMed/NCBI
5	Folprecht G, Seymour MT, Saltz L, et al: Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 26:1443–1451. 2008. View Article : Google Scholar
6	Feliu J, Escudero P, Llosa F, et al: Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J Clin Oncol. 23:3104–3111. 2005.PubMed/NCBI
7	Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 13:566–575. 2002. View Article : Google Scholar
8	Ho C, Ng K, O’Reilly S and Gill S: Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. Clin Colorectal Cancer. 5:279–282. 2005. View Article : Google Scholar : PubMed/NCBI
9	Jensen SA, Lonborg JT and Sorensen JB: Benefits and risk of palliative capecitabine-based therapy to elderly patients with advanced colorectal cancer: Danish single center experiences. Acta Oncol. 45:67–76. 2006. View Article : Google Scholar
10	Stec R, Bodnar L and Szczylik C: Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. J Cancer Res Clin Oncol. 136:283–292. 2010.PubMed/NCBI
11	Arkenau HT, Graeven U, Kubicka S, et al: Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer. 7:60–64. 2008. View Article : Google Scholar : PubMed/NCBI
12	Twelves CJ, Butts CA, Cassidy J, et al: Capecitabine/oxaliplatin, oxaliplatin a safe and active first-line regiment for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II Study. Clin Colorectal Cancer. 5:101–107. 2005. View Article : Google Scholar : PubMed/NCBI
13	Feliu J, Salud A, Escudero P, et al: XELOX (capecitabine plus oxaliplatin) as first-line treatment for patients over 70 years of age with advanced colorectal cancer. Br J Cancer. 94:969–975. 2006.PubMed/NCBI
14	Tabah-Fisch I, Maindrault-Goebel F, Benavides M, et al: Oxaliplatin/5 FU/LV is feasible, safe and active in elderly colorectal cancer (CRC) patients. ASCO abs. 556:2002.
15	Goldberg RM, Tabah-Fisch I, Bleiberg H, et al: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/lecovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 24:4085–4091. 2006. View Article : Google Scholar : PubMed/NCBI
16	Bruce C, Köhne C-H and Audisio RA: Treatment of advancedcolorectal cancer in the elderly. Eur J Surg Oncol. 84–87. 2007. View Article : Google Scholar
17	Jackson NA, Barrueco J, Soufi-Mahjoubi R, et al: Comparing safety and efficacy of first-line irinitecan/fluorropyrimidine combinations in eldery versus nonelderly patients with metastatic colorectal cancer. Cancer. 115:2617–2629. 2009. View Article : Google Scholar : PubMed/NCBI
18	Gràvalos C, River F, Massuti B, et al: Cetuximab and capecitabine as first-line treatment for elderly patient (pts) with metastatic colorectal cancer (mCRC): preliminary results of TTD trial. (suppl). J Clin Oncol. 26:2008.
19	Sastre J, Aranda E, Gràvalos C, et al: First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol. Dec. 28;2009.(Epub ahead of print).
20	Hecht JR, Mitchell E, Chidiac T, et al: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 27:672–680. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wolpin BM and Mayer RJ: Systemic treatment of colorectalcancer. Gastroenterology. 134:1296–1310. 2008. View Article : Google Scholar : PubMed/NCBI
22	Saltz L, Clarke S, Diaz-Rubio E, et al: Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first line metastatic colorectal cancer. J Clin Oncol. 25:18S2007.
23	Sama A, Gonsalves W, Aldoss I, et al: Adjuvant chemotherapy for colon cancer patients age 80 and older: Veteran’s Affairs Central Cancer (VACCR) database analysis. Gastrointestinal Cancers Symposium ASCO abs. 450:2010.
24	Köhne C-H, Folprecht G, Goldberg RM, et al: Chemotherapy in elderly patients with colorectal cancer. Oncologist. 13:390–402. 2008.
25	Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634. 2008. View Article : Google Scholar : PubMed/NCBI
26	Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI